T-cell agonists in cancer immunotherapy
Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000966.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846171403070472192 |
|---|---|
| author | Gennaro Ciliberto Aung Naing Joud Hajjar Cara L Haymaker Yeonjoo Choi Yaoyao Shi |
| author_facet | Gennaro Ciliberto Aung Naing Joud Hajjar Cara L Haymaker Yeonjoo Choi Yaoyao Shi |
| author_sort | Gennaro Ciliberto |
| collection | DOAJ |
| description | Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials. |
| format | Article |
| id | doaj-art-7ae55cbae0114c58a32f196ded238fe7 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-7ae55cbae0114c58a32f196ded238fe72024-11-10T20:45:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-10-018210.1136/jitc-2020-000966T-cell agonists in cancer immunotherapyGennaro Ciliberto0Aung Naing1Joud Hajjar2Cara L Haymaker3Yeonjoo Choi4Yaoyao Shi5Scientific Directorate, IRCSS Regina Elena National Cancer Institute, Rome, Italy14 Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAWilliam T Shearer Center for Human Immunobiology, Texas Children’s Hospital, Houston, Texas, USADepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USAInvestigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA2 Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USACancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials.https://jitc.bmj.com/content/8/2/e000966.full |
| spellingShingle | Gennaro Ciliberto Aung Naing Joud Hajjar Cara L Haymaker Yeonjoo Choi Yaoyao Shi T-cell agonists in cancer immunotherapy Journal for ImmunoTherapy of Cancer |
| title | T-cell agonists in cancer immunotherapy |
| title_full | T-cell agonists in cancer immunotherapy |
| title_fullStr | T-cell agonists in cancer immunotherapy |
| title_full_unstemmed | T-cell agonists in cancer immunotherapy |
| title_short | T-cell agonists in cancer immunotherapy |
| title_sort | t cell agonists in cancer immunotherapy |
| url | https://jitc.bmj.com/content/8/2/e000966.full |
| work_keys_str_mv | AT gennarociliberto tcellagonistsincancerimmunotherapy AT aungnaing tcellagonistsincancerimmunotherapy AT joudhajjar tcellagonistsincancerimmunotherapy AT caralhaymaker tcellagonistsincancerimmunotherapy AT yeonjoochoi tcellagonistsincancerimmunotherapy AT yaoyaoshi tcellagonistsincancerimmunotherapy |